Home> Products> global hub

{ "products": [ { "_id": "6641fd11cb05a00cc02170ba", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "R/C AIR-FLOW 250 ", "description": "R/C AIR-FLOW 250 \nSalmeterol (25mcg), Fluticasone (500mcg)\nUnderstanding R/C AIR-FLOW 250: A Comprehensive Guide to Salmeterol (25mcg) and Fluticasone (500mcg) Inhaler\nAsthma and chronic obstructive pulmonary disease (COPD) are prevalent respiratory conditions that significantly affect the quality of life of millions globally. Managing these conditions effectively requires not only a keen understanding of the disease mechanisms but also an awareness of the most effective treatments available. One such treatment is the R/C AIR-FLOW 250 inhaler, which combines Salmeterol and Fluticasone in doses of 25mcg and 500mcg respectively. This article delves into how this medication works, its benefits, and important considerations for its use.\n\nWhat is R/C AIR-FLOW 250?\nR/C AIR-FLOW 250 is a branded inhaler that delivers two medications, Salmeterol and Fluticasone, directly to the lungs through a metered-dose inhaler. Salmeterol belongs to a class of medications known as long-acting beta-agonists (LABAs), which help to relax the muscles around the airways and make breathing easier. Fluticasone, on the other hand, is a corticosteroid that reduces inflammation within the airways, thus decreasing the swelling and irritation that can cause symptoms of asthma and COPD.\n\nHow Does R/C AIR-FLOW 250 Work?\nThe combination of Salmeterol and Fluticasone in R/C AIR-FLOW 250 offers a dual approach to managing respiratory conditions:\n\nSalmeterol: As a LABA, Salmeterol works by stimulating beta-2 receptors in the lungs, which leads to the relaxation of bronchial muscles. This action helps to prevent symptoms such as wheezing, coughing, and shortness of breath over an extended period, typically lasting up to 12 hours.\n\nFluticasone: This corticosteroid works by reducing the inflammation in the airways, preventing the frequent exacerbations and worsening of symptoms that are common in chronic respiratory conditions.\n\nTogether, these medications help maintain open airways, prevent symptoms, and reduce the frequency of flare-ups, providing significant relief to patients.\n\nBenefits of Using R/C AIR-FLOW 250\nThe primary benefits of using R/C AIR-FLOW 250 include:\n\nEnhanced symptom control: The combination of a LABA and a corticosteroid offers superior control of symptoms compared to using either medication alone.\nConvenience: The formulation of two medications in one inhaler simplifies the treatment regimen, making it easier for patients to adhere to their medication schedule.\nLong-term relief: The extended action of Salmeterol provides prolonged relief from symptoms, while Fluticasone ensures reduced inflammation.\nImportant Considerations\nWhile R/C AIR-FLOW 250 is effective in managing symptoms of asthma and COPD, it is not suitable for everyone. It is essential to consider the following:\n\nNot for acute symptoms: R/C AIR-FLOW 250 is designed for long-term management and is not effective for treating acute asthma or COPD attacks.\nRegular monitoring: Patients using this inhaler should regularly consult with their healthcare provider to monitor its effectiveness and adjust the dosage if necessary.\nSide effects: Potential side effects include oral thrush, voice changes, and increased risk of infections. Using a spacer with the inhaler and rinsing the mouth after each use can help minimize some of these side effects.\n For further information: \n \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488\nhttps://www.sterisonline.com/product/r-c-air-flow-250-133710", "price": 323.0, "discountamount": 96.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "use", "life", "risk", "25mcg", "EMAIL", "LABAs", "mouth", "class", "doses", "lungs", "500mcg", "dosage", "spacer", "breath", "quality", "article", "millions", "swelling", "wheezing", "coughing", "12 hours", "everyone", "patients", "frequency", "flare-ups", "shortness", "worsening", "awareness", "Salmeterol", "irritation", "other hand", "relaxation", "infections", "combination", "one inhaler", "information", "formulation", "oral thrush", "Convenience", "Fluticasone", "inflammation", "sterispharma", "sterisonline", "COPD attacks", "acute asthma", "open airways", "CALL/WHATSAPP", "dual approach", "effectiveness", "voice changes", "acute symptoms", "inhaler should", "corticosteroid", "extended action", "two medications", "extended period", "beta-2 receptors", "superior control", "primary benefits", "prolonged relief", "Long-term relief", "bronchial muscles", "treatment regimen", "keen understanding", "disease mechanisms", "significant relief", "Regular monitoring", "healthcare provider", "Comprehensive Guide", "medication schedule", "long-term management", "acting beta-agonists", "effective treatments", "metered-dose inhaler", "Potential side effects", "frequent exacerbations", "important considerations", "R/C AIR-FLOW 250 inhaler", "Enhanced symptom control", "chronic respiratory conditions", "prevalent respiratory conditions", "chronic obstructive pulmonary disease" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1011, "imageuri": "https://bizimages.withfloats.com/actual/3f9f4c8bc5664defaf68c592b0497f56.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/3f9f4c8bc5664defaf68c592b0497f56.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-05-13T11:44:17.735Z", "updatedon": "2024-05-13T11:44:17.735Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/r-c-air-flow-250-/1011", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Salmeterol (25mcg), Fluticasone (500mcg)", "category": "ASTHMA", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662b8ff4a4eb611de48dcf1e", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET 500 ", "description": "SEIZMET 500 \nMetformin Hydrochloride\nIntroduction:\nDiabetes mellitus, a chronic metabolic disorder, poses a significant global health burden, necessitating effective management strategies to mitigate its complications. Metformin hydrochloride has long been established as a first-line therapy for type 2 diabetes mellitus (T2DM) due to its efficacy, safety profile, and cardiovascular benefits. SEIZMET 500, featuring Metformin Hydrochloride at a dosage of 500mg, represents a cornerstone in the management of T2DM. This article explores the features, efficacy, safety profile, and clinical implications of SEIZMET 500 in diabetes care.\n\nUnderstanding Metformin Hydrochloride:\nMetformin hydrochloride belongs to the class of biguanide antidiabetic medications. Its primary mechanism of action involves reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. Additionally, Metformin exerts beneficial effects on lipid metabolism and may contribute to weight loss in patients with T2DM.\n\nKey Features of SEIZMET 500:\nSEIZMET 500 is a pharmaceutical formulation containing Metformin Hydrochloride at a standardized dosage of 500mg per tablet. This dosage strength offers clinicians the flexibility to titrate doses according to individual patient needs, ensuring optimal glycemic control while minimizing the risk of adverse effects. The formulation of SEIZMET 500 ensures consistency and reliability in dosing, facilitating effective diabetes management.\n\nEfficacy in Glycemic Control:\nClinical studies have demonstrated the efficacy of Metformin Hydrochloride, including SEIZMET 500, in improving glycemic control in patients with T2DM. Metformin has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, Metformin may offer cardiovascular benefits and is associated with a reduced risk of macrovascular complications in patients with T2DM.\nFor further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/seizmet-500-134073\n\n", "price": 28.0, "discountamount": 8.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "T2DM", "class", "EMAIL", "doses", "500mg", "dosing", "action", "tablet", "SEIZMET", "article", "efficacy", "patients", "clinicians", "cornerstone", "consistency", "reliability", "information", "flexibility", "weight loss", "reduced risk", "Key Features", "Introduction", "sterisonline", "improvements", "sterispharma", "HbA1c) levels", "CALL/WHATSAPP", "diabetes care", "hemoglobin A1c", "safety profile", "plasma glucose", "adverse effects", "dosage strength", "Clinical studies", "lipid metabolism", "primary mechanism", "beneficial effects", "first-line therapy", "standardized dosage", "insulin sensitivity", "clinical implications", "Metformin Hydrochloride", "cardiovascular benefits", "optimal glycemic control", "type 2 diabetes mellitus", "individual patient needs", "peripheral glucose uptake", "pharmaceutical formulation", "overall glucose regulation", "chronic metabolic disorder", "hepatic glucose production", "macrovascular complications", "effective diabetes management", "effective management strategies", "postprandial glucose excursions", "significant global health burden", "biguanide antidiabetic medications" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 926, "imageuri": "https://bizimages.withfloats.com/actual/c5764835970c49d684fa141c57b0f065.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/c5764835970c49d684fa141c57b0f065.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-26T11:28:52.41Z", "updatedon": "2024-04-26T11:28:52.41Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/seizmet-500-/926", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Metformin Hydrochloride", "category": "Diabetic Range", "tags": [ "Glycomet", "Glyciphage", "Gluconorm", "Melmet", "Gluformin", "Cetapin", "Metsmall", "Obimet", "Metadoze" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662b85df3d1e541c580294c5", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "PIOSTERIS 30 ", "description": "PIOSTERIS 30 \nPioglitazone (30mg)\nIntroduction:\nType 2 diabetes mellitus (T2DM) presents a significant global health challenge, necessitating effective management strategies to mitigate its complications and improve patient outcomes. In recent years, Pioglitazone has emerged as a valuable therapeutic option for individuals with T2DM. PIOSTERIS 30, featuring Pioglitazone at a dosage of 30mg, represents a pivotal advancement in the armamentarium of antidiabetic medications. This article explores the features, efficacy, safety profile, and clinical implications of PIOSTERIS 30 in the management of T2DM.\n\nUnderstanding Pioglitazone:\nPioglitazone belongs to the class of thiazolidinediones (TZDs), which exert their antidiabetic effects by improving insulin sensitivity in peripheral tissues such as adipose tissue, skeletal muscle, and liver. Through activation of peroxisome proliferator-activated receptor gamma (PPAR-γ) receptors, Pioglitazone enhances glucose uptake and utilization, leading to improved glycemic control in patients with T2DM.\n\nKey Features of PIOSTERIS 30:\nPIOSTERIS 30 is a pharmaceutical formulation containing Pioglitazone at a standardized dosage of 30mg per tablet. This dosage strength offers clinicians the flexibility to tailor treatment regimens to individual patient needs, ensuring optimal glycemic control. The formulation of PIOSTERIS 30 ensures consistency and reliability in dosing, facilitating effective diabetes management.\n\nEfficacy in Glycemic Control:\nClinical studies have demonstrated the efficacy of Pioglitazone, including PIOSTERIS 30, in improving glycemic control in patients with T2DM. Pioglitazone has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, Pioglitazone may offer benefits beyond glycemic control, including improvements in insulin sensitivity and lipid profiles.\n For further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/piosteris-30-134190\n", "price": 95.0, "discountamount": 28.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "T2DM", "30mg", "TZDs", "EMAIL", "class", "liver", "dosing", "tablet", "article", "improved", "benefits", "efficacy", "patients", "PIOSTERIS", "activation", "clinicians", "utilization", "flexibility", "consistency", "reliability", "information", "individuals", "improvements", "sterispharma", "Introduction", "Pioglitazone", "Key Features", "sterisonline", "recent years", "CALL/WHATSAPP", "HbA1c) levels", "armamentarium", "complications", "lipid profiles", "glucose uptake", "safety profile", "adipose tissue", "hemoglobin A1c", "plasma glucose", "skeletal muscle", "dosage strength", "Clinical studies", "patient outcomes", "PPAR-γ) receptors", "treatment regimens", "peripheral tissues", "thiazolidinediones", "insulin sensitivity", "standardized dosage", "pivotal advancement", "antidiabetic effects", "clinical implications", "optimal glycemic control", "individual patient needs", "Type 2 diabetes mellitus", "antidiabetic medications", "pharmaceutical formulation", "overall glucose regulation", "valuable therapeutic option", "effective diabetes management", "effective management strategies", "postprandial glucose excursions", "significant global health challenge", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 922, "imageuri": "https://bizimages.withfloats.com/actual/ee3a70844d694b9c974bcaa6b13d9a19.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/ee3a70844d694b9c974bcaa6b13d9a19.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-26T10:45:51.85Z", "updatedon": "2024-04-26T10:45:51.85Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/piosteris-30-/922", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Pioglitazone (30mg)", "category": "Diabetic Range", "tags": [ "Pioz", "Pioglit", "Piosys", "Pioglar", "Pionorm", "Path", "Glitaris", "Piokind", "Piomed" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662b6aef9166a51f7ccc3178", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "LINALIGLIP DAPA 5-10 ", "description": "LINALIGLIP DAPA 5-10 \nLinagliptin 5 mg & Dapagliflozin 10 mg\nIntroduction:\nDiabetes mellitus poses a significant public health challenge, with its prevalence continuing to rise globally. In the quest for effective management strategies, the combination of multiple therapeutic agents with complementary mechanisms of action has gained traction. LINALIGLIP DAPA 5-10, a novel formulation combining Linagliptin 5 mg and Dapagliflozin 10 mg, represents a groundbreaking approach to diabetes care. This article explores the synergistic benefits, efficacy, and clinical implications of LINALIGLIP DAPA 5-10 in the management of type 2 diabetes mellitus (T2DM).\n\nUnderstanding the Mechanisms of Action:\nLINALIGLIP DAPA 5-10 combines two distinct classes of antidiabetic medications: Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Linagliptin enhances the activity of incretin hormones, such as glucagon-like peptide-1 (GLP-1), promoting insulin secretion and suppressing glucagon release. Dapagliflozin, on the other hand, inhibits renal glucose reabsorption, leading to increased urinary glucose excretion and subsequent lowering of blood glucose levels. By targeting different pathways involved in glucose regulation, LINALIGLIP DAPA 5-10 offers a comprehensive approach to glycemic control.\n\nSynergistic Benefits:\nThe combination of Linagliptin and Dapagliflozin in LINALIGLIP DAPA 5-10 provides several synergistic benefits. Firstly, the dual action of these agents targets multiple aspects of glucose homeostasis, resulting in greater reductions in hemoglobin A1c (HbA1c) levels compared to monotherapy with either component alone. Secondly, Dapagliflozin's mechanism of action leads to diuretic effects, reducing blood pressure and promoting weight loss, which complements the glucose-lowering effects of Linagliptin. Finally, the combination therapy may offer cardiovascular and renal protective benefits, as suggested by clinical trials evaluating SGLT2 inhibitors.\n For further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nBuy Now:\nhttps://www.sterisonline.com/product/linaliglip-dapa-5-10-134320\n", "price": 245.0, "discountamount": 73.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "GLP", "BUY", "T2DM", "quest", "EMAIL", "article", "efficacy", "activity", "traction", "component", "peptide-1", "other hand", "prevalence", "monotherapy", "weight loss", "dual action", "information", "Introduction", "sterispharma", "sterisonline", "transporter 2", "HbA1c) levels", "CALL/WHATSAPP", "diabetes care", "Dapagliflozin", "blood pressure", "cardiovascular", "sodium-glucose", "hemoglobin A1c", "clinical trials", "linaliglip-dapa", "LINALIGLIP DAPA", "glycemic control", "diuretic effects", "multiple aspects", "DPP-4) inhibitor", "SGLT2) inhibitor", "SGLT2 inhibitors", "glucagon release", "Linagliptin 5 mg", "novel formulation", "incretin hormones", "insulin secretion", "greater reductions", "different pathways", "glucose regulation", "subsequent lowering", "glucose homeostasis", "combination therapy", "blood glucose levels", "two distinct classes", "clinical implications", "dipeptidyl peptidase-4", "comprehensive approach", "groundbreaking approach", "antidiabetic medications", "complementary mechanisms", "glucose-lowering effects", "type 2 diabetes mellitus", "renal protective benefits", "urinary glucose excretion", "renal glucose reabsorption", "multiple therapeutic agents", "several synergistic benefits", "effective management strategies", "significant public health challenge" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 915, "imageuri": "https://bizimages.withfloats.com/actual/1f723dbe4c0848739629bd724e08ca1a.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/1f723dbe4c0848739629bd724e08ca1a.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-26T08:50:55.141Z", "updatedon": "2024-06-28T12:37:59Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/linaliglip-dapa-5-10-/915", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Linagliptin 5 mg & Dapagliflozin 10 mg", "category": "Diabetic Range", "tags": [ "Daplo-L", "Dapaone L", "Dapanova L", "Dapagza L", "Linalent-D", "Linahenz D", "Dajio L", "Linamac D", "Linapil-D", "Ondero-D" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 4, "query": null, "floatingpoint": null }